The number of genomic alterations recommended for therapy guidance in BC has steadily increased, with PIK3CA mutations, ERBB2 amplifications, NTRK fusions, MSI, TMB and ESR1 variants currently available (Table 15). This evidence concerns the gene ERBB2 and breast cancer.